PBH Stock Overview
Develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Prestige Consumer Healthcare Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.73 |
| 52 Week High | US$75.31 |
| 52 Week Low | US$52.90 |
| Beta | 0.53 |
| 1 Month Change | -7.26% |
| 3 Month Change | -6.73% |
| 1 Year Change | 9.16% |
| 3 Year Change | 30.40% |
| 5 Year Change | 121.22% |
| Change since IPO | 264.68% |
Recent News & Updates
Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22
Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Recent updates
Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jun 14Prestige Consumer Healthcare Inc. 2021 Q4 - Results - Earnings Call Presentation
May 08These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Apr 19How Much Did Prestige Consumer Healthcare's (NYSE:PBH) CEO Pocket Last Year?
Feb 22Shareholder Returns
| PBH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.6% | 0.5% | -0.2% |
| 1Y | 9.2% | 17.9% | 28.2% |
Return vs Industry: PBH underperformed the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: PBH underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| PBH volatility | |
|---|---|
| PBH Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PBH has not had significant price volatility in the past 3 months.
Volatility Over Time: PBH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 570 | Ron Lombardi | www.prestigebrands.com |
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal.
Prestige Consumer Healthcare Inc. Fundamentals Summary
| PBH fundamental statistics | |
|---|---|
| Market cap | US$3.25b |
| Earnings (TTM) | US$209.34m |
| Revenue (TTM) | US$1.13b |
15.4x
P/E Ratio2.9x
P/S RatioIs PBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBH income statement (TTM) | |
|---|---|
| Revenue | US$1.13b |
| Cost of Revenue | US$492.79m |
| Gross Profit | US$632.57m |
| Other Expenses | US$423.23m |
| Earnings | US$209.34m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.19 |
| Gross Margin | 56.21% |
| Net Profit Margin | 18.60% |
| Debt/Equity Ratio | 68.0% |
How did PBH perform over the long term?
See historical performance and comparison